CorneaGen Advances Next Generation of DSEK Surgery Innovation
April 28, 2022
New FDA approved, pre-loaded cornea graft insertion device maximizes efficiency to save precious time in the O.R.
SEATTLE (Apr. 22, 2022) – CorneaGen, innovating how ophthalmologists treat and care for every person impacted by corneal disease, today announces the release of the EndoSerter®-PL. This new and exclusive FDA approved, single-use graft insertion device is pre-loaded with expertly processed tissue to help streamline DSEK surgeries.
“We’re incredibly excited to deliver the EndoSerter®-PL, our latest innovation in advancing the next generation of cornea care” said Bernie Iliakis, President of CorneaGen. “We strive every day to better serve surgeons, patients, donor families, and industry partners through constant innovation in tissue processing technology and surgical devices.”
“Efficacy and safety are critical for surgery” said Dr. Edward Holland, Director of Cornea Services at Cincinnati Eye Institute. “With the tissue pre-loaded, surgery is significantly faster and there is less risk to mishandling of the graft. Experienced DSEK surgeons who used the original EndoSerter® insertion device are going to appreciate the benefits if the EndoSerter®-PL.”
The EndoSerter®-PL will be showcased in booth #944 at ASCRS 2022, from Apr. 22-26. Notable product demonstrations will be performed by Edward Holland, M.D., on Apr. 23, at 1:00 p.m., and John Berdahl, M.D., on Apr. 24, at 10:00 a.m.
In addition to evolving tissue processing and products, CorneaGen works as an advocate for patients. Through efforts to simplify payor reimbursement and its many industry relationships, CorneaGen serves as partner in helping all those impacted by corneal disease.
CorneaGen remains committed to transforming lives, helping deliver the gift of sight to tens of thousands of people in the U.S. every year.
CorneaGen’s mission is to provide the highest quality donor tissue, unparalleled customer service and superior products that transform how ophthalmologists treat and care for every person impacted by corneal disease. Through continuous innovations in tissue processing technology and surgical devices, advocacy for patient access and simplified payor reimbursement policies, CorneaGen is advancing the next generation of cornea care. As the world’s leading eye bank, CorneaGen has multiple locations and local partnerships throughout the U.S. to deliver the life-changing gift of sight to tens of thousands of people each year. Read more at https://corneagen.com/.
Media Inquiries for CorneaGen
Julie Fogerson, Fearey
Greg Kunst has been named chief executive officer of newly-launched...READ MORE